Fosun increased its net profit by 264% in the third quarter

Source: First Financial Daily October 29^th, 2009

Having benefited from the gain brought about by the listing of Sinopharm Group Co., Ltd (01099.HK), Fosun had its profit in the third quarter greatly increased by 264%.

The third quarter report announced today by Fosun showed that within the report period, it realized a net profit of 2.217 billion RMB, increased by 264% compared with the same period in the last year, meaning a net profit from each share is 1.79RMB. The increase in the net profit of managing the company mainly came from the product research and development as well as manufacturing business, and continuous growth in medicine commercial business, especially the listing of Sinopharm Pharmaceutical Group (01099.HK) which contributed remarkably to the increase in gain.

On September 23rd, Sinopharm Group Co., Ltd whose shares are held by Fosun was listed in the main board of Hongkong Exchanges, raising about 8.408 billion Hongkong Dollars. Fosun holds the increases in rights and interests in answer to the shares of Sinopharm Group Co., Ltd held by it. Such increase was put in the loss and profit of the current period, contributing 1.

732 billion RMB to the net profit and 1.4RMB to the gain from each share. After Sinopharm Group Co., Ltd was listed in Hongkong, the market value of it reached 63.2 billion Hongkong dollars (converted to 55.7 billion RMB) calculated based on the closing rate of 27.9 Hongkong Dollar per share on October 28th .

It is not only the largest medical type listing company in China, but also ranks among the first three in market value of listing companies whose medicine are distributed globally.

Within the report period, Fosun has its main business maintain a stable and healthy growth trend. In the first three quarters, the company s revenue was increased by 9% compared with the same period in the last year in the same range. The report of the third quarter indicated that the regular gain of Fosun had realized an increase of 25%. It is known that the increase in the regular gain of the company mainly came from medicine research, development and manufacturing business as well as the fast growth of medicine distribution business.